Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
CM

NASDAQ · CMMB

Chemomab Therapeutics Ltd.

Healthcare · Biotechnology

$2.58

Down-$0.02 (-0.77%)

Updated Sep 14, 2026, 3:18 AM

SID Score

5.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
14.53M
P/E ratio
-1.45
Dividend yield
0.00%
52-week range
$1.35 – $3.58
Volume
101.35K
Avg. volume
157.57K

Price performance

CMMB price history

1M range · 19 trading sessions · Daily adjusted prices

CMMB closed at $2.58 after 19 trading sessions, up 34.38% for the selected period.

Last close
$2.58
Period change
+34.38%
Period low
$1.91
Period high
$2.83
Daily close
View OHLC price history
CMMB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$2.66$2.76$2.56$2.58101.35K
Sep 10, 2026$2.665$2.6999$2.59$2.6023.87K
Sep 9, 2026$2.75$2.80$2.59$2.6976.86K
Sep 8, 2026$2.67$2.8792$2.66$2.7595.94K
Sep 4, 2026$2.90$2.9408$2.71$2.71118.51K
Sep 3, 2026$2.82$2.94$2.71$2.83150.84K
Sep 2, 2026$2.73$2.84$2.71$2.7347.82K
Sep 1, 2026$2.71$2.89$2.70$2.7372.56K
Aug 31, 2026$2.70$2.80$2.64$2.7242.19K
Aug 28, 2026$2.73$2.88$2.61$2.71105.16K
Aug 27, 2026$2.57$2.9895$2.57$2.72381.27K
Aug 26, 2026$2.36$2.65$2.32$2.59421.37K
Aug 25, 2026$2.12$2.37$2.12$2.30139.57K
Aug 24, 2026$2.16$2.27$2.08$2.1780.19K
Aug 21, 2026$2.06$2.20$2.04$2.16114.19K
Aug 20, 2026$2.06$2.10$1.95$2.0783.36K
Aug 19, 2026$1.96$2.11$1.8801$2.09118.77K
Aug 18, 2026$1.92$1.9201$1.87$1.9117.21K
Aug 17, 2026$2.00$2.00$1.90$1.9242.27K

Latest CMMB news

The latest Smart Investors Daily articles mentioning CMMB.

Stock researchCompany · Overview

CMMB research

Overview

Company profile and research snapshot.

Company profile

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
CMMB recent ratings
DateFirmRatingTarget
Aug 27, 2025OppenheimerOutperform—
May 16, 2025OppenheimerOutperform—
Feb 20, 2025Maxim GroupBuy—
Nov 15, 2024OppenheimerOutperform—
May 13, 2024Maxim GroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 31, 2026

Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference

TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference. Dr. Mor’s prerecorded presentation will be webcast and will be available starting on September 11, 2026 at 7:

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By